Compare AU
Compare DRUG vs. A200
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the (DRUG) and the (A200). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | A200 | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 51 | 3,368 |
Median incremental investment | $703.95 | $1,084.57 |
Median investment frequency | N/A | N/A |
Median total investment | $1,099.67 | $2,536.59 |
Average age group | N/A | N/A |
Key Summary
DRUG | A200 | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX. |
Top 3 holdings | KRW - KOREAN WON (0 %) UNITEDHEALTH GROUP INC (7.70 %) JOHNSON & JOHNSON (6.95 %) | BHP GROUP LTD (10.26 %) COMMONWEALTH BANK OF AUSTRALIA (7.91 %) CSL LTD (7.07 %) |
Top 3 industries | Other (67.01 %) Communication Services (33.53 %) Health Care (32.74 %) | Financials (27.20 %) Materials (22.98 %) Health Care (9.84 %) |
Top 3 countries | United States of America (the) (23.13 %) Switzerland (3.03 %) United Kingdom of Great Britain and Northern Ireland (the) (1.74 %) | Australia (96.56 %) New Zealand (1.24 %) Ireland (0.80 %) |
Management fee | 0.57 % | 0.04 % |
Key Summary
DRUG | A200 | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Australia 200 Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.04 % |
Price | $7.69 | $120.79 |
Size | N/A | $2.975 billion |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | - % | - % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 08/05/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | A200 | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 51 | 3,368 |
Median incremental investment | $703.95 | $1,084.57 |
Median investment frequency | N/A | N/A |
Median total investment | $1,099.67 | $2,536.59 |
Average age group | N/A | N/A |
Pros and Cons
DRUG | A200 | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | A200 |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher management fee | Lower management fee |